Topical anti-cancer compositions and methods of use thereof

Abstract
Described are skin-care compositions containing non denatured soy products and optionally other anti-cancer or anti-aging agents. The compositions can be applied topically to reduce the risk of UV-induced cutaneous tumors in skin cells that have not yet been damaged by ultraviolet radiation.
Description
FIELD OF THE INVENTION

This invention relates to compositions containing non-denatured soy products, or soy trypsin inhibitors, and optionally additional anti-cancer or cosmetically active agents. These compositions can be applied topically to reduce the risk of UV-induced cutaneous tumors.


BACKGROUND OF THE INVENTION

Skin, the largest organ of the human body, is continuously exposed to environmental insults such as smoke, pollution, and ultraviolet (UV) irradiation. The thinning of the ozone layer, which is expected to progress for at least several decades, reduces a major barrier to the passage of ultraviolet-B radiation (UVB) through the atmosphere. UVB, that is, light whose wavelength is in the range between about 280 and about 320 nm, is the main cause of sunburn, tanning, aging of the skin, and skin cancer.


The non-melanoma skin cancers (NMSC), including basal-cell and squamous-cell carcinoma, are the most common types of cancer among Caucasian populations. The incidence of NMSC has increased worldwide over the last few decades. Increased recreational and occupational sunlight exposure is commonly regarded as one of the reasons for the higher incidence of cutaneous cancers. The increase in UVB exposure associated with the thinning of the ozone layer is another significant factor. Mortality from NMSC is low, but the estimated recurrence rate of about 50% after five years and the local invasiveness of this type of cancer result in high medical costs. Therefore, NMSC constitutes a substantial public health concern. (Reviewed in Holick and Kligman, editors: Biologic effects of light. Walter de Gruyter, Berlin and New York, 1992).


Photo-carcinogenesis results from a complex interplay of simultaneous and sequential biochemical events. These events, initiated by irradiation of an organism with UV light of an appropriate wavelength, include the formation of DNA photo-products, inaccuracies in DNA repair, mutation of proto-oncogenes and tumor suppressor genes, and UV-induced production of radical species which produce subsequent effects on existing mutations and independently induce further mutations. In addition, other epigenetic events such as immunological responses, antioxidant defenses, and dietary factors may influence the course of carcinogenesis. (Black, H. S., deGruijl, F. R., Forbes P. D., Cleaver, J. E., Ananthaswamy, H. N., deFabo, E. C., Ullrich, S. E., Tyrrell, R. M., Photo-carcinogenesis: an overview. J. Photochem. Photobiol. B 40:1, 29-47, August, 1997).


The skin possesses an elaborate antioxidant defense system to deal with UV-induced oxidative stress. Excessive exposure to UV radiation, however, can overwhelm the cutaneous antioxidant capacity, leading to oxidative damage and ultimately to skin cancer and premature skin aging. Therefore, one strategy for photo-protection is to support the endogenous antioxidant system by induction or transdermal delivery of antioxidant enzymes or nonenzymatic antioxidants. Antioxidants such as glutathione, alpha-tocopherol, ascorbate and beta-carotene have been found to be very effective in photoprotection. Components of the antioxidant pathway have also been identified and applied to the skin of patients. Although skin treatments with single components of the antioxidant system such as vitamin E were successful against a wide variety of types of photodamage, they were not shown to affect the progression of UV-induced tumors. The most promising results were obtained in studies combining several compounds, which often resulted in synergy between the protective effects. (Steenvoorden D. D., van Henegouwen G. M., The use of endogenous antioxidants to improve photoprotection, J. Photochem. Photobiol., B 41:1-2, 1-10, November, 1997).


Epidemiological studies suggest that components of vegetables, particularly legumes, are beneficial in lowering the incidence rates of many types of cancer. For example, the rates of breast, colon and prostate cancer are significantly lower among the inhabitants of most countries of the Pacific Basin, but offspring of Pacific Basin natives who have migrated to the United States develop the common Western cancers at approximately the same rate as native Westerners. Such epidemiological studies suggest that dietary and other environmental factors, rather than genetic differences, contribute more significantly to the risk of susceptibility to these cancers. The high consumption of soybean products in Pacific Basin countries, such as Japan, implicates diet as one factor contributing to the relatively extremely low rates of cancer mortality in these countries. (E.g., Wu et al., Soy intake and risk of breast cancer in Asians and Asian Americans. Am. J. Clin. Nutr. 68: 6 Suppl., 1437S-1443S, December, 1998).


Soybeans are a rich source of isoflavones, which possess weak estrogenic activity. Genistein, the main soybean isoflavone, is a specific inhibitor of protein tyrosine kinases and of other enzymes involved in signal transduction. Genistein has been shown to suppress the growth of numerous cancer cells in vitro, and to protect animals in experimental carcinogenesis models from developing both hormone- and non-hormone related cancers. (Reviewed in A. R. Kennedy, Chemopreventive agents: Protease inhibitors, Pharmacology Theories 78 (3), 167-209), 1998 and in Messina et al., Soy intake and cancer risks: A review of the in vitro and in vivo data, Nutrition and Cancer 21 (2), 113-131, 1994).


Soybeans also contain a number of protease inhibitors such as BBI and STI. It is important to note that soy foods do not contain high concentrations of active STI and BBI, because these protease inhibitors block the action of trypsin and other enzymes needed for protein digestion. Although STI is denatured by cooking, heat alone does not inactivate BBI, and consumption of soy products containing high levels of these protease inhibitors leads to serious digestive problems, chronic deficiency in amino acid uptake, and cancer. Indeed, the Chinese did not serve soybeans as food until fermentation techniques were developed to destroy the anti-digestive properties of the soy foods (2nd century B.C.E.). During the production of soy foods today, pureed soybeans are soaked in an alkaline solution and then pressure-heated to 115° C. in order to denature the protease inhibitors as much as possible.


Limtrakul et al. attempted to identify a safe level of soy proteins for nutritional consumption, which would be beneficial in the prevention of cancer. Skin tumors were chemically induced in mice, which were fed soy protein isolate (SPI) exclusively, and in mice which were fed SPI supplemented with soymilk proteins (SMP). It was reported that “the percentage of tumor-bearing mice and the volume of tumor tended to be lower in the mice on the SMP diet”. Life Sciences 1993, 53, 1591-1596. When defatted soybeans are treated first with alkaline, then with acid solution, SPI is the precipitate and SMP is the supernatant. The Limtrakul study shows the potential of soy proteins to affect skin cancer progression, when the proteins are orally consumed. However, it was also emphasized that higher levels of dietary intake of SMP would result in major health problems.


It is clear that a need exists for safe, efficacious and economical agents that prevent or reduce incidence of cancer, particularly for NMSC, which may be simply and conveniently administered. Further, economical and prophylactic compositions and methods for the reduction, prevention or inhibition of the progression of UV-induced cutaneous tumors are highly desirable. Since topical application is very simple and convenient, incorporating compositions that reduce skin cancer incidence into a skin-care product would be extremely advantageous. While sunscreens are known to reduce the damage resulting from UV exposure during the period of their application, there is a need for a skin care product that could also slow the progression of already-initiated photocarcinogenic processes. It is an object of the invention to provide such a product.


SUMMARY OF THE INVENTION

The present invention provides a method of reducing the risk of developing UV-induced tumors of the skin of a mammal by topically applying a skin-care composition, preferably in a preventive, pretreatment fashion, and on a daily basis, to skin areas that might be exposed to or irradiated with UV light. A method of reducing or preventing the DNA and cellular damage induced by UV irradiation by topically applying the skin-care composition is also provided.


The skin care composition for use in the methods of the invention is formulated for the topical delivery of a non-denatured soy product (e.g., to a mammal such as a human) and comprises a soy product (e.g., a non-denatured soymilk or soybean powder or soybean trypsin inhibitor) and a vehicle. The composition may optionally comprise other anti-cancer or cosmetically active agents. Certain skin care compositions appropriate for use in the present invention have been described in U.S. patent application Ser. Nos. 09/110,409, 09/621,565 and 09/698,454, filed Jul. 6, 1998, Jul. 21, 2000 and Oct. 27, 2000, respectively, and in International Application No. WO99/04752. Each of the foregoing patent documents is incorporated herein by reference.


Other features and advantages of the present invention will be apparent to those of skill in the art in light of the following description and claims.







DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

It is believed that one skilled in the art can, based upon the description herein, utilize the present invention to its fullest extent. The following specific embodiments are to be construed as merely illustrative and not limitative of the remainder of the disclosure. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.


The present invention is directed to soy-containing compositions and methods of use thereof in the prevention and reduction of the risk of skin cancer. The novel compositions of this invention contain legume products, and preferably soy products, that may be in the form of a fluid (e.g., soymilk) or a solid (e.g., a soybean powder or soymilk powder). What is meant by “soy product” is a substance derived from the soybean, containing the ingredients naturally found in soybeans, at the relative concentrations as found in the beans, excluding water content. In one embodiment, the soy product is a non-denatured soy product.


“Denaturation” is defined in the Bantam Medical Dictionary (1990 edition) as “the change in the physical and the physiological properties of a protein, that are brought about by heat, X-rays or chemicals. These changes include loss of activity (in the case of enzymes) and loss (or alteration) of antigenicity (in the case of antigens)”.


What is meant by “non-denatured soy product” is a soy product in which the processing for the derivation of such soy product (e.g., the temperature, extraction media) did not eliminate its protease inhibitory activity. In one embodiment, the non-denatured state of the soy product of this invention is measured by the presence of an intact soybean trypsin inhibitor (STI) protein.


In another embodiment, the soy product is soymilk. One way to make soymilk is to soak the soybeans in deionized or purified water for several hours, and grind them after they were fully hydrated, with the addition of small quantities of water. (The grinding process allows the soybean milk to be extracted). After collection, the soybean milk may be filtered to remove any residual parts of the bean husk. The soymilk used in this invention can be fresh soymilk as described above, or may be made from soybean powder and water. The soybean powder is milled from soybeans and may also be lyophilized, spray dried, or freeze-dried and the resulting soymilk may or may not be filtered. Soymilk prepared by these methods may have from about 1 to about 90% by weight dry soybean powder. Another example is the use of soymilk powder, made from lyophilized, spray dried or freeze-dried soymilk, with the addition of water and finished with or without filtration or homogenization.


Other methods of soybean extraction could also be used to create the active ingredients used in this invention. In one example, the active ingredients could be extracted from ground soybeans using ethanol/water mixtures, followed by the removal of the ethanol from the extract, in such ways that the protease inhibitory activity of the soybean will be retained.


The compositions of the present invention may contain from about 1% to about 99%, by weight, of the soy product. For example, when a liquid soy product (e.g., soymilk) is used, the composition may contain from about 50% to about 99%, by weight, (e.g., from about 70% to about 99%) of the liquid soy product. For example, when a solid soy product (e.g., soybean powder or soymilk powder) is used, the composition may contain from about 1% to about 50%, by weight (e.g., from about 2% to about 30%, by weight) of the solid soy product. Compositions comprising solid soy products may also comprise water (e.g., distilled water or water contained within soymilk) to form a liquid base for the composition (e.g., to form a cream, lotion, injectable solution or gel). Such compositions may comprise from about 50% to about 98%, by weight (e.g., from about 70% to about 98%, by weight) of water. While not limited to these methods of administration, the compositions of this invention may be delivered topically, orally, or parenterally, although topical administration is preferred.


The soy products useful in this invention may be produced from all soybean species, regardless of their geographic origin, sun exposure, harvest time and the like. However, specific strains, geographic origins or growth conditions might be preferred. These include soybean strains or other legume strains particularly rich in their trypsin inhibitor (e.g. STI, LTI, BBI) content or strains in which, under the proper growth conditions trypsin inhibitor enrichment occurs in the bean. It should be noted that the legume products useful in the compositions of this invention have a distinctive odor, which may be tolerable in some cultures, but is undesired in others. If necessary, the odor of the compositions of this invention can be reduced by using soybean products derived from specific strains of soybeans known to be less odiferous, including, but not limited to, lipoxygenase-2-deficient beans and those having a modified sugar profile, or the like. A process to reduce oxygen levels in the formulation may also reduce the odor. Various masking agents or fragrances may also be used to mask the odor.


In yet another embodiment of the invention, the soy-containing compositions may optionally comprise additional synthetic or natural anti-cancer agents. Examples of such agents include, without limitation, caffeine, Milk Thistle extract, green tea extract, epigallocathechin gallate, silymarins, glucocorticoids and 5-fluorouracil.


A preferred embodiment of the invention comprises the administration of soymilk containing compositions before or after the initiation of UV-induced skin cancer. Especially preferred are embodiments in which the soymilk is not denatured, leaving STI and BBI intact. Soymilk also contains genistein and other isoflavones, and anti-oxidants such as the gamma form of vitamin E, which is essential to the health of the skin. While not wishing to be held to any particular theory, it is hypothesized that these different active components also participate in the prevention of tumor progression. Soymilk also contains lecithins and other emulsifying molecules that facilitate the transdermal delivery of the active components.


As explained above, the present invention extends to a topical cosmetic or pharmaceutical composition comprising a non-denatured soy product (e.g., a non-denatured soymilk or soybean powder) and a cosmetic or pharmaceutically acceptable vehicle and, optionally, additional anti-cancer or cosmetically active agents. As used herein, “topically applying” means directly laying on or spreading on outer skin, e.g., by use of the hands or an applicator such as a wipe, roller, or spray.


The phrase “cosmetic or pharmaceutically acceptable” refers to entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction when administered to a human. As used herein, “cosmetically acceptable” means that the ingredients which the term describes are suitable for use in contact with tissues (e.g., the skin) without undue toxicity, incompatibility, instability, irritation, allergic response, and the like.


The term “vehicle” refers to a diluent, adjuvant, excipient, or carrier. Such cosmetic or pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. In the art of formulating skin care compositions, the vehicle is often an oil-in-water or a water-in-oil emulsion. Suitable pharmaceutical carriers are described in “Remington's Pharmaceutical Sciences” by E. W. Martin. Suitable cosmetic carriers are described below.


The compositions for use in the methods of the present invention include formulations suitable for topical application to skin. In one embodiment, the composition comprises a non-denatured soy product and a cosmetically acceptable topical carrier. In one embodiment, the cosmetically acceptable topical carrier is from about 50% to about 99.99%, by weight, of the composition (e.g., from about 80% to about 99%, by weight, of the composition).


The compositions may be made into a wide variety of product types that include, but are not limited to, solutions, lotions, creams, gels, sticks, sprays, ointments, cleansing liquid washes, solid bars, shampoos, pastes, foams, powders, mousses, shaving creams, wipes, patches, nail lacquers, wound dressing, adhesive bandages, hydrogels, and films. Make-up, such as foundations, mascaras, and lipsticks also form suitable compositions. These product types may comprise several types of cosmetically acceptable topical carriers including, but not limited to solutions, emulsions (e.g., microemulsions and nanoemulsions), gels, solids and liposomes. Certain non-limitative examples of such carriers are set forth hereinbelow. Other suitable carriers may be formulated by those of ordinary skill in the art.


Topical compositions useful in the subject invention may be formulated as a solution comprising an emollient. Such compositions preferably contain from about 1% to about 50% of an emollient(s). As used herein, the term “emollient” refers to materials used for the prevention or relief of dryness, as well as for the protection of the skin. A wide variety of suitable emollients is known and may be used in the present invention. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972) and the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen, pp. 1656-61, 1626, and 1654-55 (The Cosmetic, Toiletry, and Fragrance Assoc., Washington, D.C., 7th Edition, 1997) (hereinafter “ICI Handbook”) contains numerous examples of suitable materials.


A lotion can be made from such a solution. Lotions typically comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s) and from about 50% to about 90% (e.g., from about 60% to about 80%) of water.


Another type of product that may be formulated from a solution is a cream. A cream typically comprises from about 5% to about 50% (e.g., from about 10% to about 20%) of an emollient(s) and from about 45% to about 85% (e.g., from about 50% to about 75%) of water.


Yet another type of product that may be formulated from a solution is an ointment. An ointment may comprise a simple base of animal or vegetable oils or semi-solid hydrocarbons. An ointment may comprise from about 2% to about 10% of an emollient(s) plus from about 0.1% to about 2% of a thickening agent(s). A more complete disclosure of thickening agents or viscosity increasing agents useful herein can be found in Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972) and the ICI Handbook pp. 1693-1697.


The topical compositions useful in the present invention may be formulated as emulsions. If the carrier is an emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the carrier comprises an emulsifier(s). Emulsifiers may be nonionic, anionic or cationic. Suitable emulsifiers are disclosed in, for example, in McCutcheon's Detergents and Emulsifiers, North American Edition, pp. 317-324 (1986), and the ICI Handbook, pp.1673-1686.


Lotions and creams can be formulated as emulsions. Typically such lotions comprise from 0.5% to about 5% of an emulsifier(s). Such creams would typically comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s); from about 20% to about 80% (e.g., from 30% to about 70%) of water; and from about 1% to about 10% (e.g., from about 2% to about 5%) of an emulsifier(s).


Single emulsion skin care preparations, such as lotions and creams, of the oil-in-water type and water-in-oil type are well known in the cosmetic art and are useful in the present invention. Multiphase emulsion compositions, for example the water-in-oil-in-water type, as disclosed in U.S. Pat. Nos. 4,254,105 and 4,960,764, may also be useful in the present invention. In general, such single or multiphase emulsions contain water, emollients, and emulsifiers as essential ingredients.


The topical compositions of this invention can also be formulated as a gel (e.g., an aqueous, alcohol, alcohol/water, or oil gel using a suitable gelling agent(s)). Suitable gelling agents for aqueous gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable gelling agents for oils (such as mineral oil) include, but are not limited to, hydrogenated butylene/ethylene/styrene copolymer and hydrogenated ethylene/propylene/styrene copolymer. Such gels typically comprise between about 0.1% and 5%, by weight, of such gelling agents.


The topical compositions of the present invention can also be formulated as a solid formulation (e.g., a wax-based stick, soap bar composition, powder, or a wipe containing powder).


Liposomal formulations are also useful compositions of the subject invention. In one embodiment, the soymilk or soybean powder particles or soy proteins such as STI are contained within the liposome. Examples of liposomes are unilamellar, multilamellar, and paucilamellar liposomes, which may or may not contain phospholipids. Such compositions can be prepared by first combining the non-denatured soy milk product or the STI with a phospholipid, such as dipalmitoylphosphatidyl choline, cholesterol and water. An example of a method for producing liposomes is described in Mezei & Gulasekharam, “Liposomes—A Selective Drug Delivery System for the Topical Route of Administration; Gel Dosage Form”, Journal of Pharmaceutics and Pharmacology, Vol. 34 (1982), pp. 473-474. Those of skill in the art may make suitable modifications of the method described therein.


Epidermal lipids of suitable composition for forming liposomes may be substituted for the phospholipid. The liposome preparation may then be incorporated into one of the above carriers (e.g., a gel or an oil-in-water emulsion) in order to produce the liposomal formulation. Other compositions and uses of topically applied liposomes are described in Mezei, M., “Liposomes as a Skin Drug Delivery System”, Topics in Pharmaceutical Sciences (D. Breimer and P. Speiser, eds.), Elsevier Science Publishers B. V., New York, N.Y., 1985, pp. 345-358, PCT Patent Application No. WO96/31194, Niemiec, et al., 12 Pharm. Res. 1184-88 (1995), and U.S. Pat. No. 5,260,065.


In one embodiment, the liposome is nonionic. In one example, the liposome contains (a) glycerol dilaurate; (b) compounds having the steroid backbone found in cholesterol; and (c) fatty acid ethers having from about 12 to about 18 carbon atoms. In a further embodiment, the liposome comprises glycerol dilaurate, cholesterol, polyoxyethylene-10-stearyl ether, and polyoxyethylene-9-lauryl ether. In one embodiment, these ingredients are in a ratio of about 38:12:33:17.


In one embodiment, the liposomes are present in the topical composition in an amount, based upon the total volume of the composition, of from about 5 mg/ml to about 100 mg/ml such as from about 10 mg/ml to about 50 mg/ml.


The topical compositions useful in the subject invention may contain, in addition to the aforementioned components, a wide variety of additional oil-soluble materials and/or water-soluble materials conventionally used in compositions for use on skin, hair, and nails at their art-established levels.


In addition to such agents, other emollients and surface active agents can be incorporated in the emulsions, including glycerol trioleate, acetylated sucrose distearate, sorbitan trioleate, polyoxyethylene (1) monostearate, glycerol monooleate, sucrose distearate, polyethylene glycol (50) monostearate, octylphenoxypoly (ethyleneoxy) ethanol, decaglycerin penta-isostearate, sorbitan sesquioleate, hydroxylated lanolin, lanolin, triglyceryl diisostearate, polyoxyethylene (2) oleyl ether, calcium stearoyl-2-lactylate, methyl glucoside sesquistearate, sorbitan monopalmitate, methoxy polyethylene glycol-22/dodecyl glycol copolymer (Elfacos E200), polyethylene glycol-45/dodecyl glycol copolymer (Elfacos ST9), polyethylene glycol 400 distearate, and lanolin derived sterol extracts, glycol stearate and glycerol stearate; alcohols, such as cetyl alcohol and lanolin alcohol; myristates, such as isopropyl myristate; cetyl palmitate; cholesterol; stearic acid; propylene glycol; glycerine, sorbitol and the like.


The pharmaceutical or cosmetic composition may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, depigmenting agents, darkening agents, anti-aging agents, hair removal agents, hair styling agents, nail styling agents, sunscreens, surfactants, bleaching agents, foaming agents, conditioners, humectants, fragrances, colorants, viscosifiers, buffering agents, preservatives, and the like and mixtures thereof. Skincare compositions including these components should be formulated so as not to affect the soy product or soy trypsin inhibitory activity.


Examples of humectants include glycerol, sorbitol, propylene glycol, ethylene glycol, 1,3-butylene glycol, polypropylene glycol, xylitol, malitol, lactitol, allantoin, acetamine MEA, oat protein, hyaluronic acid, and the like. They may be used either singly or in combination.


Because the compositions of this invention are non-denatured, i.e., compositions in which the protease inhibitory activity is retained, they may be more favorable as a medium for microbial growth. Preservatives are useful for substantially preventing microbial decomposition. Examples of preservatives include phenoxyethanol and parabens such as methylparaben, ethyl-paraben, and propyl-paraben; salicylic acid, chlorhexidine hydrochloride, phenoxyethanol, sodium benzoate, methyl para-hydroxybenzoate, ethyl para-hydroxybenzoate, propyl para-hydroxybenzoate, butyl para-hydroxybenzoate, isothiazolones and the like. Other examples of preservatives are listed on pages 1654-55 of the International Cosmetic Ingredient Dictionary and Handbook, eds. Wenninger and McEwen (CTFA, 7th ed., 1997), hereinafter referred to as the “Cosmetic Handbook.” The composition may comprise from about 0.01% to about 20%, by weight (more preferably, from about 0.5% to about 5%, by weight) of preservative. Microbial contamination can also be eliminated by gamma irradiation or microfiltration, or by brief heat treatments that do not result in the elimination of protease inhibitory activity.


Examples of fragrances and odor masks include menthol, anethole, carvone, eugenol, limonene, ocimene, n-decylalcohol, citronellol, a-terpineol, methyl salicylate, methyl acetate, citronellyl acetate, cineole, linalool, ethyl linalool, vanillin, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, pimento oil, cinnamon leaf oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil and the like.


Examples of surface active agents include sodium alkyl sulfates, e.g., sodium lauryl sulfate and sodium myristyl sulfate, sodium N-acyl sarcosinates, e.g., sodium N-lauroyl sarcosinate and sodium N-myristoyl sarcosinate, sodium dodecylbenzenesulfonate, sodium hydrogenated coconut fatty acid monoglyceride sulfate, sodium lauryl sulfoacetate and N-acyl glutamates, e.g., N-palmitoyl glutamate, N-methylacyltaurin sodium salt, N-methylacylalanine sodium salt, sodium α-olefin sulfonate and sodium dioctylsulfosuccinate; N-alkylaminoglycerols, e.g., N-lauryldiaminoethylglycerol and N-myristyldiaminoethylglycerol, N-alkyl-N-carboxymethylammonium betaine and sodium 2-alkyl-1-hydroxyethylimidazoline betaine; polyoxyethylenealkyl ether, polyoxyethylenealkylaryl ether, polyoxyethylenelanolin alcohol, polyoxyethyleneglyceryl monoaliphatic acid ester, polyoxyethylenesorbitol aliphatic acid ester, polyoxyethylene aliphatic acid ester, higher aliphatic acid glycerol ester, sorbitan aliphatic acid ester, Pluronic™ type surface active agent, and polyoxyethylenesorbitan aliphatic acid esters such as polyoxyethylenesorbitan monooleate and polyoxyethylenesorbitan monolaurate.


Examples of the binder or thickener include cellulose derivatives such as alkali metal salts of carboxymethylcellulose, methyl cellulose, hydroxyethyl cellulose and sodium carboxymethylhydroxyethyl cellulose, alkali metal alginates such as sodium alginate, propylene glycol alginate, gums such as carrageenan, xanthan gum, tragacanth gum, caraya gum and gum arabic, and synthetic binders such as polyvinyl alcohol, polysodium acrylate and polyvinyl pyrrolidone. Thickening agents that can be added to the compositions of this invention to alter viscosity include other polymers such as polyacrylates (e.g., polyacrylamide). Other examples of viscosity modifying agents are listed on pages 1692-97 of the Cosmetic Handbook. To achieve the appropriate viscosity, compositions of the present invention may comprise from about 0.01% to about 20%, by weight (e.g., from about 0.1% to about 5%, by weight) of a thickening agent.


Coloring agents and fragrances also are commonly included in such compositions.


In one embodiment, the topical composition further comprises another cosmetically active agent in addition to the non-denatured soy product. A “cosmetically active agent” is a compound (e.g., a synthetic compound or a compound isolated from a natural source or a natural extract) that has a cosmetic or therapeutic effect on the skin, hair, or nails, including, but not limiting to, lightening agents, darkening agents such as self-tanning agents, anti-acne agents, shine control agents, anti-microbial agents, anti-inflammatory agents, anti-mycotic agents, anti-parasite agents, external analgesics, sunscreens, photoprotectors, antioxidants, keratolytic agents, detergents/surfactants, moisturizers, nutrients, vitamins, energy enhancers, anti-perspiration agents, astringents, deodorants, hair removers, firming agents, anti-callous agents, and agents for hair, nail, and/or skin conditioning.


The compositions of this invention may be applied prior to, concurrently with or after other active ingredients or compositions to enhance their effect.


Antioxidants and/or chelating agents may also be used to increase shelf life and stability of the compositions. Antioxidants may be added both for formulation stabilization and for biological efficacy. Antioxidant compounds and their derivatives include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine), lipoic acid and dihydrolipoic acid, resveratrol, acetyl-cysteine (INIFERINE®) or lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide). Oil-soluble antioxidants suitable for use in the compositions of this invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, and ubiquinone. Natural extracts containing antioxidants suitable for use in the compositions of this invention, include, but not limited to, extracts containing flavonoids and isoflavonoids and their derivatives (e.g., genistein and diadzein), extracts containing resveratrol and the like. Examples of such natural extracts include grape seed, green tea, pine bark, propolis, and legume extracts. Other examples of antioxidants may be found on pages 1612-13 of the Cosmetic Handbook. The compositions of the present invention may comprises the antioxidant in an amount of from about 0.001% to about 20%, by weight (e.g., from about 0.01% to about 10% by weight) of the composition.


It is preferable to have at least one oil-soluble antioxidant in the compositions of this invention. The antioxidants should be utilized in a stabilizing effective amount and may range in total from about 0.001 to 10% based on the weight of the total composition, preferably from about 0.005 to about 5%. The oil-soluble antioxidants which are useful in the compositions of the present invention include butylated hydroxytoluene (BHT), ascorbyl palmitate, butylated hydroxanisole (BHA), phenyl-∀-naphthylamine, hydroquinone, propyl gallate, nordihydroguiaretic acid, and mixtures thereof as well as any other known oil-soluble antioxidant compatible with the other components of the compositions.


Preferably, a water-soluble antioxidant should also be present in the water phase of the compositions of this invention. The water-soluble antioxidants which are useful in the compositions of this invention include ascorbic acid, sodium metabisulfite, sodium bisulfite, sodium thiosulfite, sodium formaldehyde sulfoxylate, isoascorbic acid, thioglyerol, thiosorbitol, thiourea, thioglycolic acid, cysteine hydrochloride, 1,4-diazobicyclo-(2,2,2)-octane and mixtures thereof as well as any other known water-soluble antioxidant compatible with the other components of the compositions.


Chelating agents are also useful in assisting the stabilization of the compositions of this invention. Examples of chelating agents include EDTA and derivatives thereof (e.g., disodium EDTA and dipotassium EDTA), acetyl-cysteine INIFERINE®), lactoferrin, and citric acid. Other examples of chelating agents are listed on page 1626 of the Cosmetic Handbook. The compositions of the present invention may comprise the chelating agent in an amount of from about 0.001% to about 20%, by weight (e.g., from about 0.01% to about 10% by weight) of the composition.


Other active ingredients such as sunscreen materials may be utilized in the compositions of the present invention provided that they are physically and chemically compatible with the other components of the compositions. Sunscreens may include organic or inorganic sunscreens, such as methoxyoctylcinnamate and other cinnamate compounds, titanium dioxide and zinc oxide and the like.


Various irritancy mitigants may be added to the compositions of this invention. Irritancy mitigants such as α-bisabolol, panthenol, allantoin, ginkgo biloba, stearoyl glycerrhetinic acid (licorice extract), tea tree oil, butchers' broom, calendula, ginseng and the like may be added.


Other ingredients may include agents that assist in protecting the skin from aging, such as sunscreens, anti-oxidant vitamins such as ascorbic acid, vitamin B, biotin, pantothenic acid, vitamin D, vitamin E and vitamin C, and sodium bisulfite. Yeast extract, gingko biloba, bisabolol, panthenol, alpha hydroxy acids and oligosaccharides such as melibiose are among other ingredients which assist in preventing aging of the skin by such means as irritation mitigation, oxidation mitigation, healing, affecting retinoid metabolism and inhibiting the production of elastase.


The compositions of this invention may also contain other depigmenting agents in addition to the soy product. What is meant by depigmentation is the lightening of the color of an area of skin, including but not limited to, the global lightening of the user's skin tone/complexion (e.g., the face, hands, or whole body, which is uneven as a result of aging skin, or darker than desired because of ethnicity or pathology, and the like), the evening of skin color tone, or the specific lightening of age spots, freckles, or darker pigmented areas such as, but not limited to, post-inflammatory hyper-pigmentary lesions.


Examples of such depigmenting agents include, but are not limited to, lipoic acid, dihydrolipoic acid, resveratrol, ascorbic acid, kojic acid, hydroquinone, isoflavones, retinoids (e.g., retinol, retinoic acid, and retinyl palmitate), tyrosinase inhibitors, melanosome transfer inhibitors, and selective cytotoxic agents for melanocytes, or natural extracts, e.g., licorice extract, gatuline A (pilewort extract), and micromerol (butylene glycol and apple extract), providing these activities. The amount of the depigmenting agent used will depend on the activity of the compound, and will typically range from about 0.001% to about 20%, by weight (e.g., from about 0.01% to about 10%, by weight) of the composition.


Other skin color evening ingredients, such as skin darkening or sunless tanning agents, may also be effective in the skin care compositions for use in this invention.


The composition of the present invention may also contain compounds that enhance the feel of the composition on the skin of the user. Examples of such compounds include, but are not limited to, oils, silicones (e.g., siloxane polymers such as dimethicone) and skin-conditioning agents such as emollients, and humectants. Examples of such skin conditioning agents may be found of pages 1656-1670 of the Cosmetic Handbook.


Compositions which assist in the reduction of lines and wrinkles may also be added to the compositions of this invention. For example, alpha hydroxy acids, hyaluronic acid, Gatuline R (fagus silvitica extract), pigments and scattering aids such as zinc oxide and titanium dioxide may be used in the compositions of this invention in this capacity.


Anti-inflammatory agents may also be used in the compositions of this invention. Not only should these agents assist in mitigating irritation, they may assist in treating wrinkles and lines in the skin. Steroidal anti-inflammatory agents, including but not limited to, corticosteroids such as hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoxycorticosterone acetate, dexamethoasone, dichlorisone, deflorasonediacetate, diflucortolone valerate, fluadronolone, fluclarolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocionide, flucortine butylester, fluocortolone, flupredidene (flupredylidene) acetate, flurandronolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenalone acetonide, medrysone, amciafel, amcinafide, betamethasone and its esters, chlorprednisone acetate, clocortelone, clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone and mixtures thereof may be used. Preferably, hydrocortisone or natural extracts with similar activity may be used.


Nonsteroidal anti-inflammatory agents may also be employed in the compositions of this invention, such as salicylates, acetic acid derivatives, fenamates, propionic acid derivatives and pyrazoles or mixtures thereof. Other synthetic and natural anti-inflammatory agents may also be used.


Additional active ingredients having topical activity may be utilized in the compositions of this invention. Azole-type anti-fungal and anti-bacterial agents may be employed in the compositions of this invention in their base form. For example, ketoconazole, miconazole, itraconazole, elubiol, and like related imidazole antifungals and antibacterials are useful in the topical formulations of this invention.


It can be readily appreciated that a transdermal route of administration may be enhanced by use of a dermal penetration enhancer, e.g., such as enhancers described in U.S. Pat. Nos. 5,164,189, 5,008,110, and 4,879,119, issued Nov. 7, 1989 to Aruga et al. In one embodiment, a composition of the present invention can be delivered in a controlled release system, such as using a transdermal patch, liposomes, or other modes of administration. In another embodiment, polymeric materials can be used [see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Press: Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley: New York (1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J. Neurosurg. 71:105 (1989)].


In another embodiment, a controlled release system can be placed in proximity of the target tissues of the mammal, thus requiring only a fraction of the systemic dose [see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)]. In particular, a controlled release system can be introduced into an animal in proximity of the site of inappropriate immune activation or a tumor. Other controlled release systems are discussed in a review by Langer [Science 249:1527-1533 (1990)].


In yet another embodiment of the invention, the soybean trypsin inhibitor may be produced by recombinant means. The nucleotide and protein sequences of STI are known. See GenBank Accession No. AF314823. Methods for recombinant expression of STI are well known to those of ordinary skill in the art. In an alternative embodiment, the STI so produced may be modified at the genetic level (e.g. replacing amino acids to change local charges, to enhance skin penetration without compromising activity, or to enhance activity without compromising skin penetration) or chemically post synthesis (e.g. additional lipid or sugar groups) to enhance uptake of the STI into the skin of the patient.


Various and numerous methods are known in the art for transdermal administration of a drug, e.g., via a transdermal patch. Transdermal patches are described in for example, U.S. Pat. No. 5,407,713, issued Apr. 18, 1995 to Rolando et al.; U.S. Pat. No. 5,352,456, issued Oct. 4, 1004 to Fallon et al.; U.S. Pat. No. 5,332,213 issued Aug. 9, 1994 to D'Angelo et al.; U.S. Pat. No. 5,336,168, issued Aug. 9, 1994 to Sibalis; U.S. Pat. No. 5,290,561, issued Mar. 1, 1994 to Farhadieh et al.; U.S. Pat. No. 5,254,346, issued Oct. 19, 1993 to Tucker et al.; U.S. Pat. No. 5,164,189, issued Nov. 17, 1992 to Berger et al.; U.S. Pat. No. 5,163,899, issued Nov. 17, 1992 to Sibalis; U.S. Pat. Nos. 5,088,977 and 5,087,240, both issued Feb. 18, 1992 to Sibalis; U.S. Pat. No. 5,008,110, issued Apr. 16, 1991 to Benecke et al.; and U.S. Pat. No. 4,921,475, issued May 1, 1990 to Sibalis.


Compositions of the present invention may be prepared by mixing the desired ingredients. For example, soymilk is mixed with the chelating agent, preservative, and/or antioxidant. A thickener is then added to the system, and the mixture is further mixed until it reaches homogeneity at the desired viscosity. The compositions of the present invention may be prepared under an argon, nitrogen, or other inert gaseous blanket in order to enhance formulation stability and/or to reduce soybean odor. The compositions of this invention may be packaged in a tube, a sealed packet, a jar, a pump, a bottle, a can, a pledget, a towelet, a wipe or the like. An airtight package such as an aluminum tube, aluminum pocket, pump, laminate tube, or the like, can also be used to further enhance product stability.


The skin-care compositions for use in the methods of this invention may be applied daily for at least four weeks, and more preferably at least eight weeks, and most preferably on a continuous regular daily basis. Application may be continued as long as desired to maintain the condition of the skin and to reduce skin cancer risk in skin cells that have not yet been damaged.


The topically active pharmaceutical or cosmetic composition should be applied in an amount effective to effect the desired changes in the skin. As used herein, “amount effective” shall mean an amount sufficient to cover the region of skin surface where preventing cancer, inhibiting the growth rate of a cutaneous tumor, or reducing the risk of cancer is desired. Preferably, the composition is applied to the skin surface such that, based upon a cm2 of skin surface, from about 2 μl/cm2 to about 500 μl/cm2 of topically active agent is present when preventing cancer, inhibiting the growth rate of a cutaneous tumor, or reducing the risk of cancer is desired.


The following examples are provided to describe the invention in further detail. These examples are provided for illustrative purposes only, and are not to be construed as limiting the invention.


EXAMPLE 1
Preparation of Soymilk from Soybean Powder

160 g of soybean powder (Sunlight Foods, Taipei, Taiwan) was added to about 1440 g of deionized water. The mixture was stirred at room temperature for about 1 hour. The mixture was then filtered through a sieve having holes of 75 μm diameter. The filtrate resulted in about 1.1 kg of soymilk.


EXAMPLE 2
Preparation of Soymilk Gel from Soymilk

The following compositions of this invention were prepared as follows. The weight percentages of each ingredient in the compositions are indicated below in Table 2 and Table 3. First, the soymilk, as prepared in example 3, was placed into a first beaker. The preservative Phenonip® (a mixture of the preservatives methyl-paraben, propyl-paraben, ethyl-paraben, and phenoxy-ethanol sold by NIPA, Wilmington, Del.) or the preservative phenoxyethanol were added to the soymilk. Next, the chelating agent Disodium EDTA and in some examples the humectant glycerin were added to the first beaker and mixed with the soymilk. It is also possible to further add cyclomethicone, or dimethicone (tradename Dow Corning 200 Fluid®), or PolySorbate 20, or Aluminum Starch Octyl Succinate, or Sucrose Cocoate, or PEG-6 Capric/Caprylic Triglycerides to the soymilk mixture at this step as required in some examples in Table 2 and Table 3. A mixture of the thickener polyacrylamide, laureth-7, and C13-14 isoparaffins (sold by Seppic, Paris, France under the Tradename Sepigel®) was added to a second beaker along with the anti-oxidant BHT. The ingredients in the second beaker were then added to the ingredients of the first beaker and mixed until homogenous. The anti-oxidants ascorbic acid, sodium ascorbyl phosphate, lactoferrin, or tocopherol were then added to the beaker and homogeneously mixed to form the resulting gel.


EXAMPLE 3
Preparation of Soymilk Gel from Soybean Powder, Soymilk Powder or Soybean Extract

The following compositions of this invention were prepared as follows. The weight percentage of each ingredient in each of the preparations is indicated below in Table 3. First, the soymilk powder (Devansoy Farms, Carroll, Iowa) or the soybean powder (Sunlight Foods, Taipei, Taiwan) or the Soybean Extract and deionized water were placed into a first beaker and mixed to reconstitute the soy powder. The preservative Phenonip® and the chelating agent Disodium EDTA were then added to the first beaker and mixed with the soymilk. A mixture of polyacrylamide, laureth-7, and C13-14 isoparaffins was added to a second beaker along with the anti-oxidant BHT. The ingredients in the second beaker were then added to the ingredients of the first beaker and mixed until homogenous.


EXAMPLE 4
Non-denatured Soymilk Reduces the Formation of UV-induced DNA and Cellular Damage

Non-denatured soymilk (“soymilk”) was prepared as a 10% suspension in deionized water. 100 grams of soybeans (Oriental Mascot Soybeans imported from China, NY, N.Y.) were hydrated overnight in one liter of water. Soybeans were rinsed in water and then processed in one liter of water using a standard juice extractor. The fine suspension (“milk”) was collected and filtered through cheesecloth. The preservative phenoxyethanol (Phenonip, NIPA Hardwicke Inc., Wilmington, Del.) was added as 1% of the total volume and the soymilk was stored at 4° C.


Dark skinned Yucatan microswine (Charles River, Me.) were housed in appropriately sized cages in an environmentally controlled room with a 12-hour light—12-hour dark cycle and supplied with Purina mini-swine chow and water ad libitum. Animal care was based on the “Guide for the Care and Use of Laboratory Animals”, NIH Publication No. 85-23. Treatments of individual swine were always arranged in a head to tail order on one side, and in a tail to head order on the other side of the animal. A Minimal Erythemic Dose (MED) of UVB was determined for each swine by placing a plastic template with 1×1 inch2 cutouts on the dorsum of the swine. Using a UVB lamp (Model UVM-57, 302 nm lamp, UVP Inc., Upland, Calif.) placed on the template, sites were exposed to UVB for increasing times, every other day for five days. Unexposed sites were covered with the same material as the template. One MED was established as the dose that produces the least amount of visible erythema. For DNA damage studies, swine were exposed to 1.5 MED, once. Soymilk (20 □L) was applied twice a day, to a 2.5 cm2 area, for five days prior to UVB exposure, and biopsies were taken 24 hr post UVB treatment using standard techniques. To prevent a possible sunscreen effect the treated sites were cleaned with water to remove all visible residual soymilk and allowed to dry prior to the UVB exposure.


Skin biopsies were processed for histology and stained with Hematoxylin and Eosin (H&E), using standard procedures (Sheenan and Hrapckak, 1980). T-T dimer staining of swine skin sections was performed by Paragon BioServices, Inc. (Baltimore, Md.) using primary antibodies from Affitech (Oslo Research Park, Oslo, Norway). Apoptosis staining (TUNEL) was performed by Paragon Bioservices using Terminal Transferase, and Biotin-16-dUTP from Roche Diagnostics GmbH, (Mannheim, Germany).


Twenty-four hours after one UVB (1.5 MED) exposure of swine skin, T-T dimers were documented histologically in the epidermis. Pretreatment with soymilk for 5 days, once a day (20 □l/2.5 cm2), reduced, or completely eliminated the histologically detectable T-T dimers in the swine's epidermis. Similarly, apoptotic cells were documented in the epidermis following the same UVB treatment, but their presence was reduced or eliminated when the skins were pretreated with soymilk prior to UVB irradiation.


This example demonstrates that pretreatment with non-denatured soy extracts prevents or reduces the UV-induced cellular and DNA damage, that are known to be involved in the formation of skin cancer. Therefore, such a pretreatment would reduce or prevent the risk of UV-induced skin cancer.


While certain preferred embodiments of the present invention have been described and specifically exemplified above, it is not intended that the invention be limited to such embodiments. Various modifications may be made thereto without departing from the scope and spirit of the present invention, as set forth in the following claims.

Claims
  • 1. A method of reducing the risk of cutaneous tumor development in human skin, said method comprising topical application of at least one composition containing a non-denatured soy product in an amount of from about 0.01 to about 99% by weight in a carrier to human skin undamaged by ultraviolet B radiation and prior to exposure of the human skin to photocarcinogenic ultraviolet B radiation, wherein said non-denatured, soy product comprises a non-denatured, Kunitz-type soybean trypsin inhibitor.
  • 2. The method of claim 1, wherein said composition is applied at least once daily on a continuous basis.
  • 3. The method of claim 1, wherein said composition comprises 0.05-80% by weight of said soy product and is applied for at least about four to about ten weeks followed by topical application of a composition comprising 0.01-20% by weight of said soy product on a daily basis thereafter.
  • 4. The method of claim 1, wherein said composition further comprises a cosmetically acceptable vehicle.
  • 5. The method of claim 1, wherein said composition further comprises at least one anti-inflammatory agent.
  • 6. The method of claim 1, wherein said composition further comprises at least one anti-cancer agent.
  • 7. The method of claim 1, wherein said composition further comprises at least one anti-oxidant.
  • 8. The method of claim 1, wherein said composition further comprises at least one sunscreen.
  • 9. The method of claim 1, wherein said composition further comprises from about 1 to about 99% soy bean milk, from about 0.1 to about 20% emulsifier, and a preservative in an effective amount.
  • 10. The method of claim 9 wherein said composition further comprises an anti-oxidant.
  • 11. The method of claim 9, wherein said composition further composition further comprises an anti cancer agent.
  • 12. The method claim 9, wherein said composition further comprises at least one agent selected from the group consisting of anti-oxidants, sunscreens, moisturizers, bleaching agents, depigmentation agents, darkening agents, surfactants, foaming agents, conditioners, humectants, fragrances, anti-aging agents, anti-inflammatory agents, and anti-cancer agents.
  • 13. The method of claim 1, wherein said composition further comprises from about 0.1 to about 20% soy bean powder or soy milk powder, from about 0.1 to about 20% emulsifier, and a preservative in an effective amount.
  • 14. The method of claim 13, wherein said composition further comprises an anti-cancer agent.
  • 15. The method of claim 13, wherein said composition further comprises an anti-oxidant.
  • 16. The method of claim 13, wherein said composition further comprises at least one compound selected from the group consisting of anti-oxidants, sunscreens, moisturizers, bleaching agents, depigmentation agents, darkening agents, surfactants, foaming agents, conditioners, humectants, fragrances, anti-aging agents, anti-inflammatory agents, and anti-cancer agents.
  • 17. A method for reducing the risk of ultraviolet radiation-induced skin cancer in human skin, said method comprising topical application of at least one composition containing a non-denatured, soy product in an amount of from about 0.01 to about 99% by weight in a carrier to human skin undamaged by ultraviolet B radiation and prior to exposure of the human skin to photocarcinogenic ultraviolet B radiation, wherein said non-denatured, soy product comprises a non-denatured, Kunitz-type soybean trypsin inhibitor.
  • 18. The method of claim 17, wherein said composition is applied at least once daily on a continuous basis.
  • 19. The method of claim 17, wherein said soy product composition comprises from about 0.05 to about 80% by weight and is applied for at least about four to about ten weeks followed by topical application of a composition comprising 0.01-20% by weight of said soy product on a daily basis thereafter.
  • 20. The method of claim 17, wherein said composition further comprises a cosmetically acceptable vehicle.
  • 21. The method of claim 17, wherein said composition further comprises at least one anti-inflammatory agent.
  • 22. The method of claim 17, wherein said composition further comprises at least one anti-cancer agent.
  • 23. The method of claim 17, wherein said composition further comprises at least one anti-oxidant.
  • 24. The method of claim 17, wherein said composition further comprises at least one sunscreen.
  • 25. The method of claim 17, wherein said composition further comprises from about 1 to about 99% soy bean milk, from about 0.1 to about 20% emulsifier, and a preservative in an effective amount.
  • 26. The method of claim 25, wherein said composition further comprises an anti-oxidant.
  • 27. The method of claim 25, wherein said compositions further comprises an anti-cancer agent.
  • 28. The method of claim 25, wherein said composition further comprises at least one compound selected from the group consisting of anti-oxidants, sunscreens, moisturizers, bleaching agents, depigmentation agents, darkening agents, surfactants, foaming agents, conditioners, humectants, fragrances, anti-aging agents, anti-inflammatory agents, and anti-cancer agents.
  • 29. The method of claim 17, wherein said composition further comprises from about 0.1 to about 20% soy bean powder or soy milk powder, from about 0.1 to about 20% emulsifier, and a preservative in an effective amount.
  • 30. The method of claim 29, wherein said composition further comprises an anti-oxidant.
  • 31. The method of claim 29, wherein said composition further comprises an anti-cancer agent.
  • 32. The method of claim 29, wherein said composition further comprises at least one compound selected from the group consisting of anti-oxidants, sunscreens, moisturizers, bleaching agents, depigmentation agents, darkening agents, surfactants, foaming agents, conditioners, humectants, fragrances, anti-aging agents, anti-inflammatory agents, and anti-cancer agents.
  • 33. The method of claim 1, wherein said non-denatured, soy product is an isolated non-denatured, Kunitz-type soybean trypsin inhibitor.
  • 34. The method of claim 17, wherein said non-denatured, soy product is an isolated non-denatured, Kunitz-type soybean trypsin inhibitor.
  • 35. The method of claim 1, wherein said non-denatured, soy product has not been completely denatured by heat.
  • 36. The method of claim 17, wherein said non-denatured, soy product has not been completely denatured by heat.
  • 37. The method of claim 1, wherein said human skin comprises cells that do not have ultraviolet radiation induced DNA damage prior to the application of said composition.
  • 38. The method of claim 17, wherein said human skin comprises cells that do not have ultraviolet radiation induced DNA damage prior to the application of said composition.
  • 39. The method of claim 37, wherein said skin cells do not have ultraviolet radiation induced thymine dimers.
  • 40. The method of claim 38, wherein said skin cells do not have ultraviolet radiation induced thymine dimers.
  • 41. The method of claim 1, wherein said human skin is Caucasian skin.
  • 42. The method of claim 17, wherein said human skin is Caucasian skin.
CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent applications Ser. Nos. 09/698,454, filed Oct. 27, 2000, and 10/108,248 filed Mar. 27, 2002, now U.S. Pat. No. 7,309,688, the entire disclosure of which are incorporated by reference herein.

US Referenced Citations (277)
Number Name Date Kind
2924525 Kruse et al. Feb 1960 A
3097947 Kemmerer Jul 1963 A
3625976 Theimer Dec 1971 A
3755560 Dickert Aug 1973 A
4007266 Choay Feb 1977 A
4056637 Hagiwara et al. Nov 1977 A
4151304 Evans Apr 1979 A
4190671 Vanstone Feb 1980 A
4219569 Glenn Aug 1980 A
4223018 Belle Sep 1980 A
4254105 Fukuda Mar 1981 A
4272544 Cella Jun 1981 A
4278570 Flom Jul 1981 A
4279930 Hall Jul 1981 A
4297348 Frazier Oct 1981 A
4331692 Drevici May 1982 A
4333927 Ofuchi Jun 1982 A
4368187 Flom Jan 1983 A
4370315 Greff Jan 1983 A
4382960 Flom May 1983 A
4386067 Guillon May 1983 A
4421769 Dixon Dec 1983 A
4427670 Ofuchi Jan 1984 A
4434095 Chipens et al. Feb 1984 A
4437895 Koulbanis Mar 1984 A
4439418 Moller Mar 1984 A
4462981 Smith Jul 1984 A
4477434 Kosaka Oct 1984 A
4486448 Ser Dec 1984 A
4488564 Grollier Dec 1984 A
4512973 Dennis Apr 1985 A
4515778 Kastell May 1985 A
4524067 Arichi Jun 1985 A
4537782 Millet Aug 1985 A
4550035 Smith Oct 1985 A
4578267 Salamone Mar 1986 A
4584190 Tejima Apr 1986 A
4603146 Kligman Jul 1986 A
4604281 Deckner Aug 1986 A
4612192 Scheuffgen Sep 1986 A
4690821 Smith Sep 1987 A
4707293 Ferro Nov 1987 A
4727088 Scott et al. Feb 1988 A
4760096 Sakai Jul 1988 A
4793991 Slimak Dec 1988 A
4824662 Hofmann Apr 1989 A
4834076 Millet May 1989 A
4847267 Deckner Jul 1989 A
4851214 Walters Jul 1989 A
4859458 Salamone Aug 1989 A
4867964 Forestier Sep 1989 A
4871530 Grollier Oct 1989 A
4885169 Gazzani Dec 1989 A
4895839 Bombardelli Jan 1990 A
4906457 Ryan Mar 1990 A
4943462 Komerska Jul 1990 A
4960588 Hoshowski Oct 1990 A
4960764 Figueroa Oct 1990 A
4970216 Deckner Nov 1990 A
4971825 Kitazume et al. Nov 1990 A
4978528 Degre Dec 1990 A
5002761 Mueller Mar 1991 A
5006337 Motitschke et al. Apr 1991 A
5032382 Crollie Jul 1991 A
5032400 Wiersum Jul 1991 A
5043323 Bombardelli Aug 1991 A
5057417 Hammonds et al. Oct 1991 A
5077038 Hofmann Dec 1991 A
5077040 Bergmann Dec 1991 A
5104655 Bombardelli Apr 1992 A
5110603 Rau May 1992 A
5116605 Alt May 1992 A
5118671 Bombardelli Jun 1992 A
5130142 Wong et al. Jul 1992 A
5147859 Bombardelli Sep 1992 A
5166139 Bombardelli Nov 1992 A
5171577 Griat Dec 1992 A
5179091 Lesieur Jan 1993 A
5188823 Shapiro Feb 1993 A
5192332 Lang Mar 1993 A
5194252 Hofmann Mar 1993 A
5217717 Kennedy Jun 1993 A
5229104 Sottery Jul 1993 A
5231090 Hsia Jul 1993 A
5248495 Patterson Sep 1993 A
5254331 Mausner Oct 1993 A
5260065 Mathur Nov 1993 A
5270042 Whitham Dec 1993 A
5276058 Satoh Jan 1994 A
5306444 Kitamura Apr 1994 A
5310734 Losch May 1994 A
5322839 Voegeli Jun 1994 A
5352443 Kubo Oct 1994 A
5362494 Zysman Nov 1994 A
5364886 Loliger Nov 1994 A
5393519 Dowell Feb 1995 A
5397497 Jakobson Mar 1995 A
5407675 Etemad-Moghadam Apr 1995 A
5411742 Sebag May 1995 A
5427814 Loliger Jun 1995 A
5428026 Colarow Jun 1995 A
5438044 Losch Aug 1995 A
5439672 Zabotto Aug 1995 A
5443839 Meybeck Aug 1995 A
5443840 Morancais Aug 1995 A
5444092 Collins Aug 1995 A
5446605 Umehara Aug 1995 A
5466452 Whittle Nov 1995 A
5468473 Mullen Nov 1995 A
5498420 Mentrup Edgar Mar 1996 A
5503832 De Stoutz Apr 1996 A
5505946 Kennedy et al. Apr 1996 A
5510391 Elson Apr 1996 A
5523308 Costanzo Jun 1996 A
5539129 Zysman Jul 1996 A
5545399 Lee Aug 1996 A
5547661 Sun Aug 1996 A
5554647 Perricone Sep 1996 A
5565439 Piazza et al. Oct 1996 A
5565493 Nakata et al. Oct 1996 A
5567420 McEleney Oct 1996 A
5569663 Ribier Oct 1996 A
5571503 Mausner Nov 1996 A
5578297 Mellul Nov 1996 A
5589181 Bencsits Dec 1996 A
5595984 Blank Jan 1997 A
5597814 Blank Jan 1997 A
5601833 Roboer Feb 1997 A
5603949 Meybeck Feb 1997 A
5605894 Blank Feb 1997 A
5607666 Masson Mar 1997 A
5607692 Ribier Mar 1997 A
5614180 Chung Mar 1997 A
5614215 Ribier Mar 1997 A
5616572 Blank Apr 1997 A
5618522 Kaleta Apr 1997 A
5620692 Potter Apr 1997 A
5622690 Potter Apr 1997 A
5626868 Morancais May 1997 A
5629015 Ribier May 1997 A
5629301 Blank May 1997 A
5631318 Ito May 1997 A
5635165 Panitch Jun 1997 A
5637316 Ribier Jun 1997 A
5639785 Kung Jun 1997 A
5641509 Gross Jun 1997 A
5643583 Voultoury Jul 1997 A
5643587 Scancarella Jul 1997 A
5643601 Gross Jul 1997 A
5650166 Ribier Jul 1997 A
5652230 Blank Jul 1997 A
5653988 Gerber Aug 1997 A
5660853 Hansenne-Richoux Aug 1997 A
5665367 Burger Sep 1997 A
5670547 Milstein et al. Sep 1997 A
5674511 Kacher Oct 1997 A
5676935 Mellul Oct 1997 A
5676956 Duffy Oct 1997 A
5679374 Fanchon Oct 1997 A
5681571 Homgren et al. Oct 1997 A
5681852 Bissett Oct 1997 A
5683683 Scafidi Nov 1997 A
5686102 Gross Nov 1997 A
5688763 Hammonds, Jr. et al. Nov 1997 A
5691327 Blank Nov 1997 A
5712356 Bothe et al. Jan 1998 A
5723148 Love Mar 1998 A
5741496 Khaiat Apr 1998 A
5753612 Mitrani May 1998 A
5755814 Berg May 1998 A
5762916 Ansmann Jun 1998 A
5766628 Nurnberg Jun 1998 A
5776917 Blank Jul 1998 A
5780456 Blank Jul 1998 A
5780457 Blank Jul 1998 A
5780458 Blank Jul 1998 A
5780459 Blank Jul 1998 A
5786345 Blank Jul 1998 A
5786346 Blank Jul 1998 A
5789396 Blank Aug 1998 A
5795879 Blank Aug 1998 A
5801163 Blank Sep 1998 A
5804216 Terren Sep 1998 A
5807545 Coffindaffer Sep 1998 A
5824702 Wei Oct 1998 A
5833965 Sun Nov 1998 A
5834013 Ribier Nov 1998 A
5834513 Ptchelintsev Nov 1998 A
5840717 Blank Nov 1998 A
5843907 Sakai et al. Dec 1998 A
5843926 Blank Dec 1998 A
5863546 Swinehart Jan 1999 A
5869031 Tarroux et al. Feb 1999 A
5869470 Blank Feb 1999 A
5871743 Chajuss Feb 1999 A
5871823 Anders et al. Feb 1999 A
5880314 Shinomiya Mar 1999 A
5885593 Epstein Mar 1999 A
5885596 Parab Mar 1999 A
5885600 Blum Mar 1999 A
5885617 Jordan Mar 1999 A
5885948 Glenn Mar 1999 A
5888522 Pickart Mar 1999 A
5908618 Lorant Jun 1999 A
5912175 Wille, Jr. Jun 1999 A
5916577 Golz Jun 1999 A
5928654 Duranton Jul 1999 A
5928658 Kishida Jul 1999 A
5928889 Bakich Jul 1999 A
5936052 Bothe et al. Aug 1999 A
5942479 Frankenback Aug 1999 A
5945095 Mougin Aug 1999 A
5945109 Schmidt Aug 1999 A
5952373 Lanzendorfer Sep 1999 A
5958387 Bara Sep 1999 A
5961980 Kennedy Oct 1999 A
5962015 Delrieu Oct 1999 A
5962441 Blank Oct 1999 A
5965153 Allen Oct 1999 A
5972355 Knight et al. Oct 1999 A
5981450 Fabry Nov 1999 A
5985338 Suh Nov 1999 A
5985809 Frankenback Nov 1999 A
5990291 Waggle Nov 1999 A
6001367 Bazin et al. Dec 1999 A
6004915 Elliott Dec 1999 A
6013250 Cannell Jan 2000 A
6013255 Edens Jan 2000 A
6017549 Knight Jan 2000 A
6017893 Segelman Jan 2000 A
6018001 Hiratani et al. Jan 2000 A
6019962 Rabe Feb 2000 A
6030931 Vinski Feb 2000 A
6033680 Dixon Mar 2000 A
6045779 Mueller Apr 2000 A
6048520 Hoshowski Apr 2000 A
6051602 Bissett Apr 2000 A
6054137 Breton Apr 2000 A
6060070 Gorbach May 2000 A
6063398 Gueret May 2000 A
6080393 Liu et al. Jun 2000 A
6093411 Bissett Jul 2000 A
6096327 Lezdey et al. Aug 2000 A
6126933 Warne et al. Oct 2000 A
6180662 Lanzendorfer Jan 2001 B1
6183761 Bissett Feb 2001 B1
6183762 Deckers et al. Feb 2001 B1
6248350 Mori et al. Jun 2001 B1
6261603 McElwain Jul 2001 B1
6323219 Costanzo Nov 2001 B1
6399083 Pillai et al. Jun 2002 B1
6413526 Bazin et al. Jul 2002 B1
6423747 Lanzendörfer Jul 2002 B1
6433025 Lorenz Aug 2002 B1
6447809 Krumhar et al. Sep 2002 B1
6461627 Ichioka Oct 2002 B1
6555143 Miller et al. Apr 2003 B2
6558656 Mann May 2003 B2
20020034489 Wiegland Mar 2002 A1
20020035046 Lukenbach Mar 2002 A1
20020065300 Seiberg et al. May 2002 A1
20020160061 Saliou et al. Oct 2002 A1
20020160062 Liu et al. Oct 2002 A1
20020160063 Miller et al. Oct 2002 A1
20020182166 Martin Dec 2002 A1
20020192313 Saliou et al. Dec 2002 A1
20020197244 Seiberg et al. Dec 2002 A1
20030064048 Seiberg et al. Apr 2003 A1
20030224075 Liu et al. Dec 2003 A1
20040009142 Zambaux Jan 2004 A1
20040063593 Wu et al. Apr 2004 A1
20040067244 Friedman Apr 2004 A1
20050008665 Batzer Jan 2005 A1
20050019279 Goppel Jan 2005 A1
20050281776 Courcoux Dec 2005 A1
20070009459 Magnant Jan 2007 A1
20070041931 Morelli Feb 2007 A1
Foreign Referenced Citations (173)
Number Date Country
724988 May 1998 AU
1081899 Feb 1994 CN
1094279 Nov 1994 CN
1146876 Apr 1997 CN
1166960 Dec 1997 CN
4432947 Mar 1996 DE
19634206 Mar 1998 DE
19818849 Oct 1998 DE
0 273 202 Jul 1988 EP
0 341 745 Nov 1989 EP
0 393 532 Oct 1990 EP
0 421 021 Apr 1991 EP
0 473 502 Mar 1992 EP
0 476 311 Mar 1992 EP
0 508 886 Oct 1992 EP
0 574 352 Dec 1993 EP
0 581 624 Feb 1994 EP
0 581 624 Feb 1994 EP
0 582 239 Feb 1994 EP
0 582 239 Feb 1994 EP
0 643 083 Mar 1995 EP
0 643 960 Mar 1995 EP
0 655 470 May 1995 EP
0 661 037 Jul 1995 EP
0 707 851 Apr 1996 EP
0 713 106 May 1996 EP
0 758 687 Feb 1997 EP
0 774 249 May 1997 EP
0 811 595 Dec 1997 EP
0 814 116 Dec 1997 EP
0 963 761 Dec 1999 EP
1 074 240 Feb 2001 EP
1 077 063 Feb 2001 EP
1 192 938 Apr 2002 EP
1 210 946 Jun 2002 EP
1 236 402 Sep 2002 EP
1 236 465 Sep 2002 EP
1 348 441 Oct 2003 EP
1 647 278 Apr 2006 EP
2 596 986 Oct 1987 FR
2 641 696 Jul 1990 FR
2 685 202 Jun 1993 FR
2 803 747 Jul 2001 FR
2 811 226 Jan 2002 FR
1098951 Jan 1968 GB
58225003 Dec 1983 JP
58225004 Dec 1983 JP
59187756 Oct 1984 JP
60030657 Feb 1985 JP
60061513 Apr 1985 JP
62036304 Feb 1987 JP
63068512 Mar 1988 JP
63096120 Apr 1988 JP
63135310 Jun 1988 JP
63227515 Sep 1988 JP
63316711 Dec 1988 JP
1093519 Apr 1989 JP
1096106 Apr 1989 JP
02-286165 Nov 1990 JP
3127713 May 1991 JP
4169514 Jun 1992 JP
04283518 Oct 1992 JP
5015574 Jan 1993 JP
5114905 May 1993 JP
5213729 Aug 1993 JP
5246932 Sep 1993 JP
5320024 Dec 1993 JP
5320061 Dec 1993 JP
6145061 May 1994 JP
6192085 Jul 1994 JP
6256156 Sep 1994 JP
06256156 Sep 1994 JP
7010772 Jan 1995 JP
7196527 Aug 1995 JP
7196529 Aug 1995 JP
7304655 Nov 1995 JP
8012560 Jan 1996 JP
8020597 Jan 1996 JP
8040824 Feb 1996 JP
8059450 Mar 1996 JP
8099891 Apr 1996 JP
8143442 Jun 1996 JP
8333260 Dec 1996 JP
9025212 Jan 1997 JP
9025213 Jan 1997 JP
9025214 Jan 1997 JP
9059166 Mar 1997 JP
9077638 Mar 1997 JP
9176033 Jul 1997 JP
10-139654 May 1998 JP
10120542 May 1998 JP
10139654 May 1998 JP
410226642 Aug 1998 JP
11346695 Dec 1999 JP
2000302678 Oct 2000 JP
2000-351720 Dec 2000 JP
2004-000019 Jan 2004 JP
92-8851 Oct 1992 KR
92-8853 Oct 1992 KR
2066992 Sep 1996 RU
WO 8707838 Dec 1987 WO
WO 9104283 Apr 1991 WO
WO 9107166 May 1991 WO
WO 9209639 Jun 1992 WO
WO 9209650 Jun 1992 WO
WO 9406485 Mar 1994 WO
WO 9407462 Apr 1994 WO
WO 9504609 Feb 1995 WO
WO 9509002 Apr 1995 WO
WO 9509011 Apr 1995 WO
WO 9524885 Sep 1995 WO
WO 9609806 Apr 1996 WO
WO 9619483 Jun 1996 WO
WO 9619491 Jun 1996 WO
WO 9624371 Aug 1996 WO
WO 9624392 Aug 1996 WO
9628008 Sep 1996 WO
9629050 Sep 1996 WO
WO 9630035 Oct 1996 WO
WO 9630396 Oct 1996 WO
WO 9631194 Oct 1996 WO
WO 9637497 Nov 1996 WO
WO 9640121 Dec 1996 WO
WO 9640199 Dec 1996 WO
WO 9711033 Mar 1997 WO
WO 9718904 May 1997 WO
WO 9735998 Oct 1997 WO
WO 9739733 Oct 1997 WO
WO 9801107 Jan 1998 WO
WO 9802134 Jan 1998 WO
WO 9802138 Jan 1998 WO
WO 9805333 Feb 1998 WO
WO 9808503 Mar 1998 WO
WO 9809987 Mar 1998 WO
WO 9817246 Apr 1998 WO
9829091 Jul 1998 WO
WO 9833089 Jul 1998 WO
WO 9849153 Nov 1998 WO
WO 9900110 Jan 1999 WO
WO 9904752 Feb 1999 WO
WO 9909065 Feb 1999 WO
WO 9904752 Feb 1999 WO
WO 9915917 Apr 1999 WO
WO 9924003 May 1999 WO
WO 9930729 Jun 1999 WO
WO 9936050 Jul 1999 WO
WO 9939682 Aug 1999 WO
WO 9957178 Nov 1999 WO
WO 0015188 Mar 2000 WO
WO 0043049 Jul 2000 WO
WO 0051554 Sep 2000 WO
WO 0062740 Oct 2000 WO
WO 0062741 Oct 2000 WO
WO 0062743 Oct 2000 WO
WO 0062744 Oct 2000 WO
WO 0062745 Oct 2000 WO
WO 0069404 Nov 2000 WO
WO 0069406 Nov 2000 WO
WO 0069407 Nov 2000 WO
WO 0069408 Nov 2000 WO
WO 0074699 Dec 2000 WO
WO 0134099 May 2001 WO
WO 0134909 May 2001 WO
WO 0135920 May 2001 WO
WO 0207697 Jan 2002 WO
WO 0207697 Jan 2002 WO
WO 02064104 Aug 2002 WO
WO 02067988 Sep 2002 WO
WO 02074280 Sep 2002 WO
WO 03032941 Apr 2003 WO
WO 03039502 May 2003 WO
WO 2004022024 Mar 2004 WO
WO 2005097216 Oct 2005 WO
Non-Patent Literature Citations (177)
Entry
Andrews et al. “Bacterial Survey of Sixty Health Foods”. Applied and Environmental Microbiology. 1979. vol. 37, No. 3. pp. 559-566.
Matsuura et al. “Objectionable Flavor of Soy Milk Developed during the Soaking of Soybeans and its Control”. Journal of Food Science. 1989. vol. 54, No. 3. pp. 602-605.
Kunitz (J. Gen. Physiol. 29 (1946) 149-154).
Joles et al, Br J Radiol, 39 (1966) pp. 12-18.
“A Combined Soybean Crushing-Deordorizing System that Yields 100-200 Mesh Powder for Food Additive Use has been Developed by Shinyu Zoki Co. Ltd. And Mitsubishi Rayon Engineering Ltd.”, Tech Times, pp. 10 (1978).
“Avon's Anew Positivity Trio Targets Menopausal Women”, The Rose Sheet, Feb. 28, 2000, p. 8.
“CaspACE™ Assay System, Colorimetric”, Product Improvements, Neural Notes vol. V, Issue 1, p. 13 (1999) Promega Corporation.
“Elhibin®” Product Brochure, PENTAPHARM, Centerchem, Inc., Stamford, CT, publicly available prior to Feb. 28, 2001.
“EnzChek® Protease Assay Kits” Product Information, MP06638, pp. 1-4, Revised Feb. 25, 2001, Molecular Probes, Eugene, OR.
“Flavosterone S (Soybean Extract Contained Iso-Flavone”, Ichimaru Pharcos Co., Ltd. pp. 11-13 (Dec. 22, 1998).
“Isoral Soybean power makes your skin clear and moist!”—Brochure, publicly available prior to Feb. 28, 2001.
“Lipoxydase Code 411784”, Lipoxydase File Apr. 1999, A LIBiol Body Care Composition.
“Nudit Advertisement”, publicly available prior to Feb. 28, 2001.
“Patent Abstracts—Gastric Juice for Antiaging 1997”.
“Patent Abstracts—Plant extracts for skin whitening”, publicly available prior to Feb. 28, 2001.
“Patent Abstracts—Soybeans for skin pigmentation 1997”.
“Patent Abstracts—Soybeans for skin whitening 1997”.
“Patent Abstracts of requested patent titles 1996”.
“Patent List—Thrombin Inhibitors: List of Relevant Patent Applications as of Jul. 8, 1998, and Oct. 1, 1996.”
“Plant Extract Containing Female Hormone-Like Isoflavones—Flavosterone”, leaflet from Ichimaru Pharcos issued Mar. 7, 1997.
“Product for Damaged hair by Bristol-Myers-Squibb”, (Abstract) publicly available prior to Feb. 28, 2001.
“RQ1 RNase-Free DNASE”, Promega Corporation, Technical Bulletin No. 518, pp. 1-4, Feb. 2000, Part#TB518, Promega Corporation, 2800 Woods Hollow Rd., Madison, WI 53711-5399.
“Soy Protein Prevents Skin Tumors From Developing in Mice”, Gene Therapy Weekly, ISSN 1078-2842, pp. 21 (Nov. 8, 2001).
“Soy Therapy”, www.wiseessentials.com/soytherapy.html (email from Jue-Chen Liu, Ph.D. to Cunero et al dated Apr. 13, 2000) Wise Essentials.
“Soybean Technology Improves Skin”, Allured's Cosmetics & Toiletries Magazine, vol. 115, No. 3, Mar. 2000, p. 22.
“Superscript II Reverse Transciptase” protocol published by Gibco-BRL (now Life Tech Inc.) Apr. 1992.
“The Joy of Soy”, www.wheat-grass.com/851—oral—liquid.shtml, Wheatgrass Express, Inc., 1996.
“ThermoScript™ RNase H-Reverse Transcriptase”, Invitrogen™ Life Technologies, www.invitrogen.com/content.cfm, Invitrogen Corporation, 2001.
“Whitening with Soybean? HR has launched “Future White” in Japan”, Helena Rubinstein, publicly available prior to Feb. 28, 2001.
Ahrens et al, “Photocarcinogenesis and Inhibition of Intercellular Adhesion Molecular I Expression in Cells of DNA-Repair-Defective Individuals”, Proc. National Academy of Sciences, vol. 94 (1997) pp. 6837-6841.
Badash et al, “Effect of Gamma Irradiation of Field and Storage Fungi of Wheat, Maize and Soybean”, Chemie Mikrobiologie Technologie der Lebensmittel (1992).
Balsam et al, Cosmetics, Science and Technology, 2nd Edition, vol. 1, pp. 32-43 (1972).
Balsam et al, Cosmetics, Science and Technology, 2nd Edition, vol. 1, pp. 72-73 (1972).
Barbuch et al, “The Use of Thermospray Liquid Chromatography/Tandem Mass Spectrometry for the Class Identification and Structural Verification of Phytoestrogens in Soy Protein Preparations”, Biomedical and Environmental Mass Spectrometry, vol. 18 (1989) pp. 973-977.
Barel et al, “Suction Method for Measurement of Skin Mechanical Properties: The Cutometer®”, Chapter 14.3, pp. 335-340, Handbook of Non-Invasive Methods and the Skin, Jorgen Serup and G.B.E. Jemec (1995).
Batista et al, “Primary Structure of a Kunitz-Type Trypsin Inhibitor From Enterolobium Contortisiliquum Seeds”, Phytochemistry, vol. 41, No. 4, (1996) pp. 1017-1022.
Benshimol, “The Biochemistry and Nutrition Group: 30 Years of Research in a Developing Country”, Archivos LatinoAmericanos De Nutrician, vol. 44, No. 4-S, pp. 6-S-9-S (1994).
Billings et al, “A Growth-Regulated Protease Activity that is Inhibited by the Anticarcinogenic Bowman-Birk Protease Inhibitor”, Pro. Natl. Acad. Sci., vol. 89, pp. 3120-3124 (1992).
Birk, “Protein Proteinase Inhibitors in Legume Seeds—Overview”, Archivos Latinoamericanos de Nutricion, vol. 44, No. 4-S (1994) pp. 26-S-30-S.
Birk, “The Bowman-Birk Inhibitor—Trypsin- and Chymotrypsin-Inhibitor from Soybeans”, Int. J. Peptide Protein Res., vol. 25, pp. 113-131 (1985).
Blackheart et al, “Ligand Cross-Reactivity Within the Protease-Activated Receptor Family”, The Journal of Biological Chemistry, vol. 271, No. 28, pp. 16466-16471 (1996).
Bonifacino et al, “Electrophoresis and Immunoblotting”, Chapter 6, pp. 6.0.1-6.6.1, Current Protocols in Cell Biology, copyright 2000 by John Wiley & Sons, Inc.
Brass et al, “Protease-Activated G Protein Coupled Receptors on Human Platelets and Endothelial Cells”, F.K. Schattauer Vertagsgesellschaft mbH (Stuttgart), vol. 78, No. 1, pp. 234-241 (1997).
Chomczynski et al, “Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction,” Analytical Biochemistry, vol. 162, pp. 156-159 (1987).
Clark et al, “Tryptase Inhibitors Block Allergen-induced Airway and Inflammatory Responses in Allergic Sheep”, American Journal of Respiratory and Critical Care Medicine, vol. 152, pp. 2076-2083, 1995.
Connor et al, “Depletion of Cutaneous Glutathione by Ultraviolet Radiation”, Photochemistry and Photobiology, vol. 46, No. 2, pp. 239-245 (1987).
Costanzo et al, “Potent Thrombin Inhibitors That Probe the S1 Subsite: Tripeptide Transition State Analogues Based on a Heterocycle Activated Carbonyl Group”, J. Med. Chem., vol. 39, 1996, pp. 3039-3043.
Couglin, “Protease Activated Receptors Start a Family”, Proc. Natl. Acad. Sci. USA, vol. 91, 1994, pp. 9200-9202.
Covelli et al, “Diazepam Inhibits Phagocytosis and Killing Exerted by Polymorphonuclear Cells and Monocytes From Healthy Donors”, Abstract, Immunopharmacology and Immunotoxicology, vol. 11, No. 4 (1989) pp. 701-714, copyright © 1989 by Marcel Dekker, Inc.
Cunniff, “Official Methods of Anaysis of AOAC International”, 16th Adition, 5th Revision (1999) AOAC International.
De Seidl, “Interaction of Proteases with Legume Seed Inhibitors, Molecular Features”, Archivos Latinoamericanos de Nutricion, vol. 44, No. 4-S (1994) pp. 21-S-25-S.
Derian et al, “Differential Regulation of Human Keratinocyte Growth and Differentiation by a Novel Family of Protease-activated Receptors”; Cell Growth & Differentiation, vol. 8, pp. 743-749, Jul. 1997.
Dewitt et al, “Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer's Disease”, Experimental Neurology, vol. 149, Article No. EN976738 (1998) pp. 329-340.
Doolittle, “Proteins”, Reading from Scientific American—The Molecules of Life, Chapter 4, pp. 38-47 (1985).
Doring, “The Role of Neutrophil Elastase in Chronic Inflammation”, American Journal of Respiratory and Critical Care Medicine, vol. 150, 1994, pp. S114-S117.
Dunaevsky et al, “Two Groups of Protease Inhibitors Functionally Active in Buckwheat Seeds”, soba.shinshu-uac.jp/contents/105.html, publicly available prior to Feb. 28, 2001.
Dunaevsky et al, “Isolation and Properties of Anionic Protease Inhibitors from Buckwheat Seeds”, Biochemistry and Molecular Biology International, vol. 40, No. 1, (Sep. 1996) pp. 199-208.
Ebling et al, “Hair”, Journal of Investigative Dermatology, vol. 67, No. 1, pp. 98-105 (Jul. 1976).
Ebling, “Hair Follicles and Associated Glands as Androgen Targets”, Clinics in Endocrinology and Metabolism, vol. 15, No. 2, pp. 319-339 (May 1986).
Fagerholm et al, “The Effect of a Drug-delivery System Consisting of Soybean Phosphatidyl Choline and Medium-chain Monoacylglycerol on the Intestinal Permeability of Hexarelin in the Rat”, J. Pharm. Pharmacol. (1998) vol. 50, pp. 467-473.
Fimiani et al, “Mid-Dermal Elastolysis; An Ultrastructural and Biochemical Study”, Arch. Dermatol Res., vol. 287, (1995) pp. 152-157.
Fox et al, “Identification of Potential Activators of Proteinase-Activated Receptor-2”, Federation of European Biochemical Societies, FEBS Letters 417 (1997) pp. 267-269.
Galvez et al, “Chemopreventive Property of a Soybean Peptide (Lunasin) That Binds to Deacetylated Histones and Inhibits Acetylation”, Cancer Research, vol. 61, No. 20, pp. 7473-7478 (Oct. 15, 2001).
Grant-Theule, “Periodontal Disease, Diabetes, and Immune Response: A Review of Current Concepts”, Peridontal Abstracts, vol. 44, No. 3, 1996, pp. 69-77.
Greenberger, “Immunologic Aspects of Lung Diseases and Cystic Fibrosis”, JAMA, vol. 278, No. 22 (1997) pp. 1924-1930.
Guo et al, “A Serine Protease From Suspension-Cultured Soybean Cells”, Phytochemistry, vol. 47, No. 4 (1998) pp. 547-553.
Hachimi et al, “Do Microglial Cells Phagocyte the B/A4-Amylold Senile Plaque Core of Alzheimer Diesease?”, C.R. Academy of Science, Paris, Sciences de la vie/Life sciences, vol. 317, 1994, pp. 445-451.
Hacker, “Common Disorders of Pigmentation—When are more than cosmetic cover-ups required?”, Postgraduate Medicine, vol. 99, No. 6, 1996, pp. 177-186.
Hafez et al, “Effects of Gamma Irradiation on Proteins and Fatty Acids of Soybean”, Journal of Food Science, vol. 50 (1985) pp. 1271-1274.
Hamada, “Evaluation of the Effects of Hair Re-growth Agents on Lengthening the Anagen Phase Period and Blockade of Anagen phase-Catagen phase Transformation”, J. Soc. Cosmet. Chem. Japan, vol. 31, No. 4 (1997) pp. 413-419.
Hanada et al, “Photoprotective Effect of Esterified Glutathione Against Ultraviolet B-Induced Sunburn Cell Formation in the Hairless Mice”, The Journal of Investigative Dermatology, vol. 108, No. 5, pp. 727-730 (1997).
Hasler et al, “Nutrition Communique, Soy: Just a Hill of Beans?”, Journal of Women's Health, vol. 7, No. 5 (1998) pp. 519-523.
Hattori et al, “Effects of sup.60 Co-gamma-rays on Defatted Soybean Powder”, Food Irradiation, vol. 3, No. 1, pp. 104-110 (1968).
Hayashi et al, “Inhibition of Serine Proteases of the Blood Coagulation System by Squash Family Protease Inhibitors”, J. Biochem., vol. 116, No. 5, pp. 1013-1018 (1994).
Hendrich et al, “Defining Food Components as New Nutrients”, American Institute of Nutrition, Food Composition (1994) pp. 1789S-1792S.
Hoff et al, “Macrophage Uptake of Cholesterol-Containing Particles Derived From LDL and Isolated From Atherosclerotic Lesions”, European Heart Journal, vol. 11, Supplement E, 1990, pp. 105-115.
Hollenberg et al, “Protelnase-Activated Receptor-2 in Rat Aorta: Structural Requirements for Agonist Activity of Receptor-Activating Peptides”, Molecular Pharmacology, vol. 49, pp. 229-233 (1996).
Itami et al, “Mechanism of Action of Androgen in Hair Follicles”, Journal of Dermatological Science, 7 Suppl., S98-S103 (Jul. 1994).
Jimenez et al, “Mammalian Tyrosinase: Biosynthesis, Processing and Modulation by Melanocyte Stimulating Hormone”, Proc. Natl. Acad. Sci. USA (1988), vol. 85, pp. 3830-3834.
Jimenez et al, “Specific Identification of an Authentic Clone for Mammalian Tyrosinase”, The Journal of Biological Chemistry, (1989) vol. 264, No. 6, pp. 3397-3403.
Jingtian et al, “Studies of Soy Sauce Sterlization and its Special Flavour Improvement by Gamma-Ray Irradiation”, Radiation Physics and Chemistry, vol. 31, Nos. 1-3, pp. 209-213 (1988).
Keeton et al, “The Chemistry of Life”, Biological Science, Fourth Edition, Chapter 3, pp. 66-67 (1986).
Kennedy et al, “Prevention of Carcinogenesis by Protease Inhibitors”, Cancer Research, vol. 54, No. 7 (Suppl), pp. 1999s-2005s (Apr. 1, 1994).
Kennedy, “The Evidence for Soybean Products as Cancer Preventive Agents”, The Journal of Nutrition, vol. 125, No. 3 Suppl, pp. 733s-743s (Mar. 1995).
Kennedy, “Chemopreventive Agents: Protease Inhibitors,” Pharmacol. Ther., vol. 78, No. 3, pp. 167-209, 1998, Copyright 1998 Elsevier Science Inc.
Kennedy, “The Bowman Birk Inhibitor from Soybeans as an Anticarcinogenic Agent”, American Journal of Clinical Nutrition, vol. 68(suppl), pp. 1406S-1412S (1998).
Kovacs et al, “Effect of Irradiation and Dielectric Heating on Soybean Ultrastructure, Trypsin Inhibitor, and Lipoxygenase Activities”, Food Structure, vol. 10, pp. 217-227 (1991).
Lam et al, “Combined Effect of Irradiation and Dielectric Heating on Chemical Properties of Soybeans”, 7th Symp. on Radiation Chemistry, pp. 477-483 (1990).
Limtrakul et al, “Suppressive Effect of Soybean Milk Protein on Experimentally Induced Skin Tumor in Mice”, Life Sciences, vol. 53 (1993) pp. 1591-1596.
Liu et al, “Aqueous Ethanol Extraction of Soybean Trypsin Inhibitors and Characterization of a Calcium-Sensitive Fraction”, Journal of Food Biochemistry, vol. 15 (1991) pp. 159-168.
Liu, “Chemistry and Nutritional Value of Soybean Components”, in Soybeans, Chemistry, Technology and Utilization, pp. 32-35 (copyright © 1997 by Chapman & Hall).
MacFarlane et al, “Refractory Periodontitis Associated With Abnormal Polymorphonuclear Leukocyte Phagocytosis and Cigarette Smoking”, J. Peridontal, vol. 63, No. 11, Nov. 1992, pp. 908-913.
Maes et al, “Leukocytosis, Monocytosis and Neutrophilla: Hallmarks of Severe Depression”, J. Psychiat. Res., vol. 26, No. 2 (1992) pp. 125-134.
Mahoney et al, “Amino Acid Sequence and Secondary Structural Analysis of the Corn Inhibitor of Trypsin and Activated Hageman Factor”, Journal of Biological Chemistry, vol. 259, No. 13 (Jul. 10, 1984) pp. 8412-8416.
McAdams et al, “Neutrophil and Monocyte Phagocytosis in Depressed Patients”, Prog. Neuro-Psychopharmacol & Biol. Psychiat (1993) vol. 17, pp. 971-984.
McCutcheon's Emulsifiers and Detergents 1986, North American Edition, McCutcheon Division, Mc Publishing Co., Glen Rock, New Jersey, pp. 317-324 (1986).
Meister, “Glutathione, Ascorbate, and Cellular Protection”, Cancer Research, vol. 54, pp. 1969s-1975s (1994).
Merck Index (12th Edition), Edited by Susan Budavari (1996) Thrombin., entry 9525, p. 1601.
Merck Index (12th Edition), Edited by Susan Budavari (1996) Trypsin, entry 9926, p. 1669.
Mercola, “Concerns Regarding Soybeans”, www.rheumatic.org/soy.htm, publicly available prior to Feb. 28, 2001.
Messina, “Soy Intake and Cancer Risk: A Review of the In Vitro and In Vivo Data”, Nutrician and Cancer, vol. 21, No. 2 (1994) pp. 113-131.
Mezei et al, “Liposomes—A Selective Drug Delivery System for the Topical Route of Administration: Gel Dosage Form”, Journal of Pharmaceutics and Pharmacology, vol. 34 (1982), pp. 473-474.
Mezei, “Liposomes as a Skin Drug Delivery System”, Topics in Pharmaceutical Sciences (D. D. Breimer and P. Speiser, eds.,), Elsevier Science Publishers B. V., New York, N.Y., 1985, pp. 345-358.
Miyagi et al, “Trypsin Inhibitor Activity in Commercial Soybean Products in Japan”, J. Nutr. Sci. Vitaminol (1997) vol. 43, pp. 575-580.
Molinari et al, “Inhaled Tryptase Causes Bronchoconstriction in Sheep Via Histamine Release”, American Journal of Respiratory and Critical Care Medicine, vol. 154, pp. 649-653, 1996.
Molino et al, “Interactions of Mast Cell Tryptase with Thrombin Receptors and PAR-2”, Journal of Biological Chemistry, vol. 272, No. 7, Feb. 14, 1997, pp. 4043-4049.
Morita et al, “Partial Purification and Characterization of a Novel Soybean Protease Which is Inhibited by Kunitz and Bowman-Birk Trypsin Inhibitors”, J. Biochem., vol. 119, No. 4, 1996, pp. 711-718.
Mulimani et al, “Effect of Heat Treatments on Trypsin/Chyomotrypsin Inhibitor Activity of Red Gram (Cajanus cajan L.)”, Plant Foods for Human Nutrition, vol. 46, No. 2, (1994) pp. 103-107.
Mulimani et al, “Effects of Heat Treatment and Germination on Trypsin and Chymotrypsin Inhibitory Activities in Sorghum (Sorghum bicolor (L.) Moench) Seeds”, Plant Foods for Human Nutrition, vol. 44, No. 3 (1993) pp. 221-226.
Murphy, “Phytoestrogen Content of Processed Soybean Products”, Food Technology, vol. 1, pp. 60-64 (1982).
Musclow et al., “Fluorescence Assay to Monitor Phagocytosis by Blood-Clot Derived Polymorphonuclear Leucocytes, 1 Study of Patients With Diabetes and Phagocytosis of Different Staphyloccoccal Species”, Cytoblos, vol. 65, 1991, pp. 15-24 (published and (C) 1991 by the Faculty Press, Cambridge, Great Britain).
Mysliborski et al, “Therapy for Acne Vulgaris”, Comprehensive Therapy, vol. 7, No. 1, pp. 13-16 (Jan. 1981).
Niemiec et al., “Influence of Nonionic Liposomal Composition on Topical Delivery of Peptide Drugs into Pilosebaceous Units: An In Vivo Study Using the Hamster Ear Model”, Pharmaceutical Research, vol. 12, No. 8, 1995, pp. 1184-1188.
Odani et al, “Studies on Soybean Trypsin Inhibitors. XIII. Preparation and Characterization of Active Fragments from Bowman-Birk Proteinase Inhibitor”, Journal Biochem., vol. 83, No. 3, pp. 747-753 (1978).
Odani et al., “Wheat Germ Trypsin Inhibitors. Isolation and Structural Characterization of Single-Headed and Double-Headed Inhibitors of the Bowman-Birk Type”, J. Biochem., vol. 100, pp. 975-983 (1986).
Official Compendia of Standards, USP 24 USP/NF 19, US Pharmacopeial Convention, Inc. 2000 (Board of Trustees, US Pharmacopieal Convention, Inc.).
Ogawa, “Current Problem of Research on Hair Growth Mechanisms and Hair Growth Promotors”, Fragrance Journal, vol. 5, pp. 1-5 (1989).
Orlow et al, “Subcellular Distribution of Tyrosinase and Tyrosinase-Related Protein-1: Implications for Melanosomal Biogenesis”, The Journal of Investigative Dermatology, Inc., vol. 100, No. 1, Jan. 1993, pp. 55-64.
Quillien et al, “Trypsin Inhibitor Polymorphism: Multigene Family Expression and Posttranslational Modification”, Journal of Protein Chemistry, vol. 16, No. 3 (1997) pp. 195-203.
Reiner, “Altered Cell Signaling and Mononuclear Phagocyte Deactivation During Interacellular Infection”, Immunology Today, vol. 15, No. 8 (1994) pp. 374-381.
Ripka et al, “Chapter 8: Antithrombotics/Serine Protease”, Covads International, San Diego, CA, publicly available prior to Feb. 28, 2001.
Robert et al, “Cell-Matrix Interactions in the Genesis of Arteriosclerosis and Alateroma, Effect of Aging”, Laboratorie de Biologie du Tissu Conjonctif, Annals New York Academy of Sciences, 1992, pp. 331-341.
Santulli et al, “Evidence for the Presence of a Protease-Activated Receptor Distinct from the Thrombin Receptor in Human Keratinocytes”, Proceeding of the National Academy of Sciences USA, vol. 92, Sep. 1995, pp. 9151-9155.
Scotti, “Soy-derived Protease Inhibitors Treat Cancer and Inflammation”, Windhover Information Inc. (1998).
Seiberg et al, “Trypsin-Induced Follicular Papilla Apoptosis Results in Delayed Hair Growth and Pigmentation”, Developmental Dynamics, vol. 208, pp. 553-564 (1997).
Sessa et al, “Toasted Soybean Flour Components with Trypsin Inhibitor Activity”, JAOCS, vol. 63, No. 6, pp. 784-788 (Jun. 1986).
Setchell, “High-Performance Liquid Chromatographic Analysis of Phytoestrogens in Soy Protein Preparations with Ultraviolet Electrochemical and Thermospray Mass Spectrometric Detection”, Journal of Chromotography, vol. 386 (1987) pp. 315-323, CHROMSYMP. 956.
Sharpell et al, “Preservation of Cosmetics”, Chapter 51, pp. 887-900, Disinfection, Sterilization and Preservation, 4th Edition, Seymour S. Block, Ph. D., Lea & Febiger (1991) publicly available prior to Feb. 28, 2001.
Sligh Jr. et al, “Inflammatory and Immune Responses are Imparied in Mice Deficient in Intercellular Adhesion Molecule 1”, Proc. Natl. Acad., Sci. USA, vol. 90, 1993, pp. 8529-8533.
Song et al, “PS04.01.44 Crystal Structure of the Complex of Porcine Pancreatic Trypsin with Kunitz-Type Soybean Trypsin Inhibitor”, Crystallography of Biological Macromolecules, p. C-106, XVII Congress and General Assembly of the International Union of Crystallog, (1996) (www.bmsc.wahing...ts/abstracts/S0081.html).
Song et al, “Kunitz-Type Soybean Trypsin Inhibitor Revisited: Refined Structure of its Complex with Porcine Trypsin Reveals an Insight into the Interaction Between a Homologous Inhibitor from Erythrina caffra and Tissue-type Plasminogen Activator”, J. Mol. Biol., vol. 275, pp. 347-363 (1998).
Steenvoorden et al, “Protection Against UV-Induced Reactive Intermediate in Human Cells and Mouse Skin by Glutathione Precursos: A Comparison of N-Acetylcysteine and Glutathione Ethylester”, Photochemistry and Photobiology, vol. 67, No. 6, pp. 651-656 (1998).
Steenvoorden et al, “The Use of Endogenous Antioxidants to Improve Photoprotection”, Journal of Photochemistry and Photobiology B: Biology, vol. 41 (1997) pp. 1-10.
Stenn et al, “Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration,” Skin Pharmocol., vol. 6, pp. 125-134 (1993).
Tan-Wilson, “Relevance of Multiple Soybean Trypsin Inhibitor Forms to Nutritional Quality”, Nutritional and Toxicological Significance of Enzyme Inhibitors in Foods, Edited by Mendel Friedman, Chapter 22, pp. 391-411 (1985), Department of Biological Sciences, State University of New York at Binghamton.
Tashiro et al., “The Complete Amino Acid Sequence of Rice Bran Trypsin Inhibitor”, J. Biochem, vol. 102, No. 2, pp. 297-306 (1987).
Terada et al, “Amino Acid Sequences of Double-headed Proteinase Inhibitors from the Seeds of Canavalia lineata”, Biosci. Biotech. Biochem., vol. 58, No. 2, pp. 376-379 (1994).
Thornton et al, “Effect of Androgens on the Growth of Cultured Human Dermal Papilla Cells Derived from Beard and Scalp Hair Follicles”, The Journal of Investigative Dermatology, vol. 97, No. 2, pp. 345-348 (Aug. 1991).
Travis et al, “The Role of Proteolytic Enzymes in the Development of Pumonary Emphysema and Periodontal Disease”, American Journal of Respiratory and Critical Care Medicine, vol. 150,1994, pp. S143-S146.
Tronnier et al., “Adhesion Molecule Expression in Normal Skin and Melanocytic Lesions”, Journal of Cutaneous Pathology, vol. 24, 1997, pp. 278-285.
Tyrrell et al., “Correlation Between Endogenous Glutathione Content and Sensitivity of Cultured Human Skin Cells to Radiation at Defined Wavelengths in the Solar Ultraviolet Range”, Photochemistry and Photobiology, vol. 47, No. 3, pp. 405-412 (1988).
Van De Stolpe et al, “Intercellular Adhesion Molecule-1”, J. Mol. Med., vol. 74, 1996, pp. 13-33.
Van Den Broeke et al, “Topically Applied N-acetylcysteine as a Protector Against UVB-Induced Systemic Immunosuppression”, Journal of Photochemistry and Photobiology, B: Biology, vol. 27, pp. 61-65 (1995).
Wang et al, “Effects of Soybean Trypsin Inhibitor on Digestive Physiology and Growth and Development of Helicoverpa Armigera Larvae”, Acta Entomologica Sinica, vol. 38, No. 3 (Aug. 1995) pp. 272-274.
Webster, “Inflammation in Acne Vulgaris”, Journal of the American Academy of Dermatology, vol. 33, No. 2, Part 1, 1995, pp. 247-253.
Wiley et al, “Cardiovascular and Renal-Small-molecule direct thrombin inhibitors”, Exp. Opin. Ther. Patents, vol. 7, No. 11, 1997, pp. 1265-1282 (Ashley Publications Ltd. ISSN 1354-3776).
Xiang et al, “A Study of Nexin 1 of Skin and Hair Follicle during Postnatal Development Period of Rat”, Zhongguo Yi Xue Ke Xue Yaun Xue Bao, vol. 20, No. 2, pp. 127-132 (Apr. 1998) Abstract.
Yu et al, “Message of Nexin 1, a Serine Protease Inhibitor, is Accumulated in the Follicular Papilla During Anagen of the Hair Cycle”, Journal of Cell Science, vol. 108, Pt 12 (Dec. 1995) pp. 3867-3874 Abstract.
U.S. Appl. No. 10/611,100, filed Jul. 1, 2003, Halas et al.
U.S. Appl. No. 09/110,409, filed Jul. 6, 1998, Seiberg et al.
U.S. Appl. No. 10/659,598, filed Sep. 10, 2003, Seiberg et al.
U.S. Appl. No. 09/206,249, filed Dec. 7, 1998, Seiberg et al.
U.S. Appl. No. 09/677,511, filed Sep. 29, 2000, Liu et al.
U.S. Appl. No. 09/621,565, filed Jul. 20, 2000, Seiberg et al.
U.S. Appl. No. 10/434,309, filed May 8, 2003, Seiberg et al.
Babiarz-Magee et al, “The Expression and Activation of Protease-Activated Receptor-2 Correlate with Skin Color”, Pigment Cell Res, vol. 17 (2004) pp. 241-251.
Hermanns et al, “Unraveling the Patterns of Subclinical Pheomelanin-Enriched Facial Hyperpigmentation: Effect of Depigmenting Agents”, Dermatology, vol. 201 (2000) pp. 118-122.
Liu et al, “Application of Soy in Skin Care”, Journal Nutr., vol. 132 (2002) pp. 574S.
Paine et al, “An Alternative Approach to Depigmentation by Soybean Extracts via Inhibition of the PAR-2 Pathway”, Journal Investigative Dermatology, vol. 116 (2001) pp. 587-595.
Scott et al, “Protease-Activated Receptor 2, a Receptor Involved in Melanosome Transfer, is Upregulated in Human Skin by Ultraviolet Irradiation”, Journal Investigative Dermatology, vol. 117 (2001) pp. 1412-1420.
Scott et al, “Proteinase-Activated Receptor-2 Stimulates Prostaglandin Production in Keratinocytes: Analysis of Prostaglandin Receptors on Human Melanocytes and Effects of PGE2 and PGF2α on Melanocyte Dendricity”, Journal Investigative Dermatology, vol. 122 (2004) pp. 1214-1224.
Scott et al, “The Proteinase-Activated Receptor-2 Mediates Phagocytosis in a Pho-Dependent Manner in Human Keratinocytes”, Journal Investigative Dermatology, vol. 121 (2003) pp. 529-541.
Seiberg et al, “Inhibition of Melanosome Transfer Results in Skin Lightening”, Journal Investigative Dermatology, vol. 115 (2000) pp. 162-167.
Seiberg et al, “Soy Extracts Reduce Hair Growth and Hair Follicle Dimensions”, Hair Science and Technology, D. Van Neste (editor) (2003) pp. 391-400.
Seiberg et al, “Soymilk Reduces Hair Growth and Hair Follicle Dimensions”, Experimental Dermatology, vol. 10 (2001) pp. 405-423.
Seiberg et al, “The Protease-Activated Receptor 2 Regulates Pigmentation via Keratinocyte-Melanocyte Interactions”, Experimental Cell Research, vol. 254 (2000) pp. 25-32.
Seiberg et al, “The Protease-Activated Receptor-2 Regulates Pigmentation via Melanosome Phagocytosis”, Mechanisms of Suntanning, J. P. Ortonne and R. Ballotti (editors) (2002) pp. 215-278.
Seiberg et al, “The Regulation of Pigmentation by Serine Proteases and Their Inhibitors”, Inhibition of Human Proteases: From Target Identification to Therapy, CHI Press (1998) pp. 1-3.
Seiberg, “Keratinocyte-Melanocyte Interactions During Melanosome Transfer”, Pigment Cell Res., vol. 14 (2001) pp. 236-242.
Sharlow et al, “The Protease-Activated Receptor-2 Upregulates Keratinocyte Phagocytosis”, Journal of Cell Science, vol. 113 (2000) pp. 3093-3101.
Wilson et al, “Immunocytochemical Study of the Interaction of Soybean Trypsin Inhibitor with Rat Intestinal Mucosa”, Gut, vol. 19 (1978) pp. 260-266.
Ogawa, “Current Problem of Research on Hair Growth Mechanisms and Hair Growth Promoters”, Fragrance Journal, vol. 5, pp. 1-5 (1989).
Uniqema: “Pharmaceutical and Cosmetic Uses of Diolic Acids”, Research Disclosure, Kenneth Mason Publications, Hampshire, GB, vol. 444, No. 77 (Apr. 2001.
Huang et al: “Inhibitory Effect of Topical Applications of Nondenatured Soymilk on the Formation and Growth of UVB-Induced Skin Tumors”, Oncology Research, vol. 14 (2004) pp. 387-397.
McGuire, J.S. “Activation of Epidermal Tyrosinase.” Biochemical and Biophysical Communications, 40(5): 1084-1089 (1970).
http://familydoctor.org/online/famdocen/home/common/cancer/risk/159.html; published Jan. 1996.
http://www.faqs.org/health/Sick-V1/Acne.html, accessed Oct. 31, 2006.
Related Publications (1)
Number Date Country
20040062731 A1 Apr 2004 US
Continuation in Parts (2)
Number Date Country
Parent 10108248 Mar 2002 US
Child 10689149 US
Parent 09698454 Oct 2000 US
Child 10108248 US